The expression of Lin-CD11b+CD33+ MDSCs was increased at diagnosis (38.6 ± 6.5%) compared with MMR (11.8 ± 2.5%, p = 0.0004) and CD4+CD25highCD127-Foxp3+ Tregs was higher at diagnosis (2.3 ± 0.2%) compared with MMR (1.8 ± 0.2%, p = 0.02) (158) indicating the treatment of CML may require a combination of TKI and immunotherapy. The gene discussed is CD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.